Effects	effects	O	O	O	O
of	of	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
symptoms	symptoms	O	O	O	O
and	and	O	O	O	O
postcibal	postcibal	O	O	O	O
small-bowel	small-bowel	O	O	O	O
motor	motor	O	O	O	O
function	function	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
irritable	irritable	O	DISEASE	OTHERS	I
bowel	bowel	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Irritable	irritable	O	DISEASE	OTHERS	I
bowel	bowel	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
common	common	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
abdominal	abdominal	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
and	and	O	O	O	O
discomfort	discomfort	O	O	O	O
and	and	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
disordered	disordered	O	O	OTHERS	I
gastrointestinal	gastrointestinal	O	O	OTHERS	I
motility	motility	O	O	OTHERS	I
.	.	O	O	O	O

Our	our	O	O	O	O
aim	aim	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
long-term	long-term	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
prokinetic	prokinetic	O	O	O	O
agent	agent	O	O	O	O
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
on	on	O	O	O	O
postprandial	postprandial	O	O	O	O
jejunal	jejunal	O	O	O	O
motility	motility	O	O	O	O
and	and	O	O	O	O
symptoms	symptoms	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
irritable	irritable	O	DISEASE	OTHERS	I
bowel	bowel	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
IBS	ibs	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Thirty-eight	thirty-eight	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
IBS	ibs	O	O	OTHERS	I
(	(	O	O	O	O
constipation-predominant	constipation-predominant	O	O	O	O
,	,	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
17	17	O	O	O	O
;	;	O	O	O	O
diarrhoea-predominant	diarrhoea-predominant	O	O	O	O
,	,	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
21	21	O	O	O	O
)	)	O	O	O	O
underwent	underwent	O	O	O	O
24-h	24-h	O	O	O	O
ambulatory	ambulatory	O	O	O	O
jejunal	jejunal	O	O	O	O
manometry	manometry	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
12	12	O	O	O	O
week	week	O	O	O	O
's	's	O	O	O	O
treatment	treatment	O	O	O	O
[	[	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
5	5	O	O	O	O
mg	mg	O	O	OTHERS	I
three	three	O	O	O	O
times	times	O	O	O	O
daily	daily	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
19	19	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
19	19	O	O	O	O
)	)	O	O	O	O
]	]	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
diarrhoea-predominant	diarrhoea-predominant	O	O	O	O
patients	patients	O	O	O	O
significant	significant	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
contraction	contraction	O	O	O	O
characteristics	characteristics	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
placebo	placebo	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
cisapride-treated	cisapride-treated	O	O	O	O
diarrhoea-predominant	diarrhoea-predominant	O	O	O	O
patients	patients	O	O	O	O
the	the	O	O	O	O
mean	mean	O	O	O	O
contraction	contraction	O	O	O	O
amplitude	amplitude	O	O	O	O
was	was	O	O	O	O
higher	higher	O	O	O	O
(	(	O	O	O	O
29.3	29.3	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
3.2	3.2	O	O	O	O
versus	versus	O	O	O	O
24.9	24.9	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
2.6	2.6	O	O	O	O
mm	mm	O	O	OTHERS	I
Hg	hg	O	O	OTHERS	I
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
25.7	25.7	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
6.0	6.0	O	O	O	O
mm	mm	O	O	OTHERS	I
Hg	hg	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
mean	mean	O	O	O	O
contraction	contraction	O	O	O	O
duration	duration	O	O	O	O
longer	longer	O	O	O	O
(	(	O	O	O	O
3.4	3.4	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.2	0.2	O	O	O	O
versus	versus	O	O	O	O
3.0	3.0	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.2	0.2	O	O	O	O
sec	sec	O	O	O	O
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
3.1	3.1	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.5	0.5	O	O	O	O
sec	sec	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
mean	mean	O	O	O	O
contraction	contraction	O	O	O	O
frequency	frequency	O	O	O	O
lower	lower	O	O	O	O
(	(	O	O	O	O
2.0	2.0	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.2	0.2	O	O	O	O
versus	versus	O	O	O	O
2.5	2.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.4	0.4	O	O	O	O
cont./min	cont./min	O	O	O	O
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
2.5	2.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.1	1.1	O	O	O	O
cont./min	cont./min	O	O	O	O
]	]	O	O	O	O
than	than	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
placebo	placebo	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
significant	significant	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
jejunal	jejunal	O	O	O	O
motility	motility	O	O	O	O
were	were	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
constipation-predominant	constipation-predominant	O	O	O	O
IBS	ibs	O	O	OTHERS	I
group	group	O	O	O	O
.	.	O	O	O	O

Symptoms	symptoms	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
visual	visual	O	O	O	O
analogue	analogue	O	O	O	O
scale	scale	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Symptom	symptom	O	O	O	O
scores	scores	O	O	O	O
relating	relating	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
constipation	constipation	O	DISEASE	OTHERS	I
were	were	O	O	O	O
lower	lower	O	O	O	O
in	in	O	O	O	O
cisapride-treated	cisapride-treated	O	O	O	O
constipation-predominant	constipation-predominant	O	O	O	O
IBS	ibs	O	O	OTHERS	I
patients	patients	O	O	O	O
[	[	O	O	O	O
score	score	O	O	O	O
,	,	O	O	O	O
54	54	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
5	5	O	O	O	O
versus	versus	O	O	O	O
67	67	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
14	14	O	O	O	O
mm	mm	O	O	OTHERS	I
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
62	62	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
19	19	O	O	O	O
mm	mm	O	O	OTHERS	I
]	]	O	O	O	O
.	.	O	O	O	O

Diarrhoea-predominant	diarrhoea-predominant	O	O	O	O
IBS	ibs	O	O	OTHERS	I
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
score	score	O	O	O	O
after	after	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
[	[	O	O	O	O
score	score	O	O	O	O
,	,	O	O	O	O
55	55	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
15	15	O	O	O	O
versus	versus	O	O	O	O
34	34	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
12	12	O	O	O	O
mm	mm	O	O	OTHERS	I
,	,	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
67	67	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
19	19	O	O	O	O
mm	mm	O	O	OTHERS	I
]	]	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Cisapride	cisapride	CHEMICALS	O	OTHERS	I
affects	affects	O	O	O	O
jejunal	jejunal	O	O	O	O
contraction	contraction	O	O	O	O
characteristics	characteristics	O	O	O	O
and	and	O	O	O	O
some	some	O	O	O	O
symptoms	symptoms	O	O	O	O
in	in	O	O	O	O
IBS	ibs	O	O	OTHERS	I
.	.	O	O	O	O

